文献速递重症综合管理与镇静镇痛儿科与产科急症消化、代谢与肾脏急症

儿童重症血液净化治疗应用现状分析

[Analysis of the current application status of blood purification therapy in critically ill children].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2026-01-01
一句话结论单中心回顾性队列显示,2017至2024年395例接受持续血液净化的危重患儿死亡率为22.8%,2021至2024年组死亡率较2017至2020年组降低(18.8% vs. 30.6%)。

该研究为单中心回顾性队列,纳入宁波大学附属妇女儿童医院2017年1月至2024年12月接受持续血液净化(CBP)治疗的395例危重患儿,分析临床特征、治疗模式选择及预后影响因素。主要原发病为脓毒症(27.1%)、肾衰竭(25.3%)和急性中毒(24.1%);主要治疗模式为持续静脉-静脉血液透析滤过(CVVHDF,60.8%);总死亡率为22.8%。与2017至2020年组相比,2021至2024年组死亡率降低(18.8% vs. 30.6%),区域枸橼酸抗凝比例升高(5.7% vs. 0.7%),合并多器官功能障碍综合征比例降低(33.0% vs. 50.0%),住院时间缩短(11.0天 vs. 17.0天),均P<0.05。作者认为优化抗凝策略、改进血管通路选择及早期干预有望进一步降低死亡率、改善预后。

要点

  • 395例接受CBP的危重患儿中,305例存活、90例死亡,总死亡率22.8%。
  • 非存活组较存活组年龄更小(38.0个月 vs. 100.0个月)、体重更低(12.3 kg vs. 22.5 kg),合并MODS比例更高(95.6% vs. 22.0%),使用血管活性药物比例更高(92.2% vs. 20.3%),机械通气比例更高(100% vs. 40.7%),ECMO支持比例更高(5.6% vs. 0.7%),住院时间更短(9.0天 vs. 15.0天),均P<0.05。
  • 2021至2024年组较2017至2020年组死亡率降低(18.8% vs. 30.6%),区域枸橼酸抗凝比例升高(5.7% vs. 0.7%),合并MODS比例降低(33.0% vs. 50.0%),住院时间缩短(11.0天 vs. 17.0天),均P<0.05。
  • 主要CBP模式为CVVHDF(60.8%),其次为血液灌流(15.7%)、治疗性血浆置换(9.1%)和杂交血液净化治疗(14.4%);主要血管通路为右颈内静脉(51.1%),主要抗凝方式为全身肝素抗凝(93.7%)。
  • 并发症总发生率为15.2%(60/395),主要为血小板减少和导管相关感染。

适用人群与场景

  • 2017年1月至2024年12月在宁波大学附属妇女儿童医院接受持续血液净化(CBP)治疗的危重患儿395例,其中男性219例、女性176例,中位年龄78(24,157)个月,中位体重18(12,40)kg。
  • 按治疗时期分为2017至2020年组134例和2021至2024年组261例。

处置流程与药物剂量

  • 主要CBP治疗模式为持续静脉-静脉血液透析滤过(CVVHDF),占60.8%(240/395);其次为血液灌流(HP)15.7%(62/395)、治疗性血浆置换(TPE)9.1%(36/395)和杂交血液净化治疗(HBPT)14.4%(57/395)。
  • 主要血管通路为右颈内静脉,占51.1%(202/395)。
  • 主要抗凝方式为全身肝素抗凝,占93.7%(370/395);2021至2024年组区域枸橼酸抗凝比例为5.7%(15/261),高于2017至2020年组的0.7%(1/134),P<0.05。

研究设计与关键结果

  • 研究类型为单中心回顾性队列研究,纳入395例接受CBP治疗的危重患儿,主要原发病依次为脓毒症27.1%(107/395)、肾衰竭25.3%(100/395)、急性中毒24.1%(95/395)。
  • 总死亡率为22.8%(90/395),存活305例。
  • 非存活组与存活组比较:年龄更小[38.0(6.0,72.5)个月 vs. 100.0(30.0,159.0)个月]、体重更低[12.3(7.0,20.0)kg vs. 22.5(13.0,43.0)kg]、合并MODS比例更高[95.6%(86/90)vs. 22.0%(67/305)]、使用血管活性药物比例更高[92.2%(83/90)vs. 20.3%(62/305)]、机械通气比例更高[100%(90/90)vs. 40.7%(124/305)]、ECMO支持比例更高[5.6%(5/90)vs. 0.7%(2/305)]、住院时间更短[9.0(3.8,16.3)天 vs. 15.0(9.0,26.0)天],均P<0.05;非存活组原发病为坏死性脑病、高钠血症、噬血细胞综合征及先天性心脏病术后修复的比例更高(均P<0.05)。
  • 2021至2024年组与2017至2020年组比较:年龄更大[102.0(28.0,160.5)个月 vs. 42.0(17.0,102.0)个月]、体重更高[18.5(13.0,45.0)kg vs. 15.0(11.0,29.0)kg]、总死亡率降低[18.8%(49/261)vs. 30.6%(41/134)]、右颈内静脉作为血管通路比例更高、区域枸橼酸抗凝比例升高[5.7%(15/261)vs. 0.7%(1/134)]、合并MODS比例降低[33.0%(86/261)vs. 50.0%(67/134)]、ECMO支持率升高[2.7%(7/261)vs. 0%(0/134)]、住院时间缩短[11.0(6.0,21.0)天 vs. 17.0(12.0,34.0)天],均P<0.05;2021至2024年组原发病中脓毒症比例更低、肾衰竭比例更高(均P<0.05)。
  • 并发症总发生率为15.2%(60/395),主要为血小板减少和导管相关感染。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,CBP是危重患儿的有效治疗手段,其疗效与患者年龄、基础疾病及所需器官支持程度密切相关。
  • 作者认为,优化抗凝策略、改进血管通路选择及实施早期干预有望进一步降低死亡率、改善预后。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To analyze the clinical features, treatment mode selection, factors influencing prognosis and current clinical application of continuous blood purification (CBP) in critically ill children in a tertiary hospital in the Ningbo region, and provide evidence for optimizing critical care strategies for pediatric patients.

METHODS: A retrospective cohort study was conducted, enrolling 395 critically ill children who underwent CBP treatment at the Women and Children's Hospital of Ningbo University from January 2017 to December 2024. Clinical data of the children were collected and analyzed, including general demographic characteristics, distribution of primary diseases, CBP treatment-related parameters (including vascular access, anticoagulation method, and treatment mode), and prognosis. The children were divided into the survival group and the non-survival group according to their prognosis, and further stratified into the 2017-2020 group and the 2021-2024 group based on the treatment period. Clinical characteristics, intervention measures, and prognosis-related indicators were compared among different groups to explore the temporal trends in CBP application and the influencing factors of prognosis.

RESULTS: A total of 395 children were enrolled, including 219 males and 176 females. The median age was 78 (24, 157) months, and the median body weight was 18 (12, 40) kg. Among them, 305 cases survived and 90 cases died, with a mortality of 22.8%. According to the treatment period, 134 cases were assigned to the 2017-2020 group and 261 cases to the 2021-2024 group. The main primary diseases were sepsis [27.1% (107/395)], renal failure [25.3% (100/395)], and acute poisoning [24.1% (95/395)] in order of frequency. The predominant CBP treatment mode was continuous veno-venous hemodiafiltration [CVVHDF; 60.8% (240/395), followed by hemoperfusion [HP; 15.7% (62/395)], therapeutic plasma exchange [TPE; 9.1% (36/395)], and hybrid blood purification treatment [HBPT; 14.4% (57/395)]. The right internal jugular vein was the main vascular access [51.1% (202/395)], and systemic heparin anticoagulation was the primary anticoagulation method [93.7% (370/395)]. The overall incidence of complications was 15.2% (60/395), mainly including thrombocytopenia and catheter-related infection. Compared with the survival group, the non-survival group had significantly younger age [months: 38.0 (6.0, 72.5) vs. 100.0 (30.0, 159.0)], lower body weight [kg: 12.3 (7.0, 20.0) vs. 22.5 (13.0, 43.0)], higher proportions of combined multiple organ dysfunction syndrome [MODS; 95.6% (86/90) vs. 22.0% (67/305)], use of vasoactive drugs [92.2% (83/90) vs. 20.3% (62/305)], mechanical ventilation [100% (90/90) vs. 40.7% (124/305)], and extracorporeal membrane oxygenation (ECMO) support [5.6% (5/90) vs. 0.7% (2/305)], as well as shorter hospital stay [days: 9.0 (3.8, 16.3) vs. 15.0 (9.0, 26.0)], all P<0.05. Additionally, the non-survival group had higher proportions of primary diseases including necrotizing encephalopathy, hypernatremia, hemophagocytic syndrome, and post-congenital heart disease surgery (all P<0.05). Compared with the 2017-2020 group, the 2021-2024 group showed significantly increased age [months: 102.0 (28.0, 160.5) vs. 42.0 (17.0, 102.0)] and body weight [kg: 18.5 (13.0, 45.0) vs. 15.0 (11.0, 29.0)], decreased overall mortality rate [18.8% (49/261) vs. 30.6% (41/134)], higher proportion of right internal jugular vein as vascular access, increased ratio of regional citrate anticoagulation [5.7% (15/261) vs. 0.7% (1/134)], reduced proportion of combined MODS [33.0% (86/261) vs. 50.0% (67/134)], elevated rate of ECMO support [2.7% (7/261) vs. 0% (0/134)], and shortened hospital stay [days: 11.0 (6.0, 21.0) vs. 17.0 (12.0, 34.0)], all P<0.05. Moreover, the 2021-2024 group had a lower proportion of sepsis and a higher proportion of renal failure among primary diseases (both P<0.05).

CONCLUSIONS: CBP represents a valuable therapeutic modality for critically ill children. Its efficacy is closely linked to patient age, the underlying disease, and the extent of organ support required. Optimizing anticoagulation strategies, improving vascular access selection, and implementing early intervention hold promise for further reducing mortality and improving prognosis.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zheng Y, Ruan P, Wang J, et al. [Analysis of the current application status of blood purification therapy in critically ill children]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026. PMID: 41958132. doi:10.3760/cma.j.cn121430-20250625-00608

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。